ONTOLOGY REPORT - ANNOTATIONS
| Term: | flurbiprofen |
|
| Accession: | CHEBI:5130
|
browse the term
|
| Definition: | A fluorobiphenyl that has formula C15H13FO2. |
| Synonyms: | exact_synonym: | 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid |
| | related_synonym: | (+-)-2-fluoro-alpha-methyl-4-biphenylacetic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 3-fluoro-4-phenylhydratropic acid; Ansaid; C15H13FO2; CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1; InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18); InChIKey=SYTBZMRGLBWNTM-UHFFFAOYSA-N |
| | xref_casrn: | 5104-49-4 |
| | xref: | Beilstein:2054451 "Beilstein Registry Number"; ChEMBL:116308 "ChEMBL COMPOUND"; ChemIDplus:5104-49-4 "CAS Registry Number"; DrugBank:DB00712 "DrugBank"; KEGG DRUG:5104-49-4 "CAS Registry Number"; KEGG DRUG:D00330 "KEGG DRUG" |
| | xref_mesh: | MESH:D005480 |
| | xref: | Wikipedia:Flurbiprofen "Wikipedia" |
|
|
flurbiprofen
|
| G |
Acta1 |
actin, alpha 1, skeletal muscle |
|
decreases expression |
ISO |
19 |
54,081,496 |
54,084,508 |
RGD:6480464 |
CTD |
| G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
|
decreases expression |
ISO |
4 |
61,794,352 |
61,806,916 |
RGD:6480464 |
CTD |
| G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
|
decreases activity |
ISO |
17 |
77,084,306 |
77,112,994 |
RGD:6480464 |
CTD |
| G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
decreases activity |
ISO |
17 |
77,034,737 |
77,081,406 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
decreases activity |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
decreases activity |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
decreases activity |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects binding |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
|
decreases expression |
ISO |
18 |
52,300,899 |
52,333,149 |
RGD:6480464 |
CTD |
| G |
Anp32a |
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A |
|
increases expression |
ISO |
8 |
66,488,188 |
66,523,421 |
RGD:6480464 |
CTD |
| G |
Anxa1 |
annexin A1 |
|
increases expression |
ISO |
1 |
223,478,436 |
223,494,455 |
RGD:6480464 |
CTD |
| G |
Anxa3 |
annexin A3 |
|
increases expression |
ISO |
14 |
14,245,112 |
14,297,100 |
RGD:6480464 |
CTD |
| G |
Apod |
apolipoprotein D |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Apof |
apolipoprotein F |
|
increases expression |
ISO |
7 |
1,562,515 |
1,563,953 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
affects cleavage |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
EXP |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
decreases secretion |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Arg1 |
arginase, liver |
|
decreases expression |
ISO |
1 |
20,998,894 |
21,011,275 |
RGD:6480464 |
CTD |
| G |
Asic1 |
acid-sensing (proton-gated) ion channel 1 |
|
decreases activity |
EXP |
7 |
138,414,656 |
138,443,272 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
|
increases expression |
ISO |
1 |
198,683,009 |
198,700,075 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
EXP |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
decreases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ceacam1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
increases expression |
ISO |
1 |
80,742,540 |
80,758,943 |
RGD:6480464 |
CTD |
| G |
Ces1d |
carboxylesterase 1D |
|
decreases expression |
ISO |
19 |
14,928,539 |
14,967,082 |
RGD:6480464 |
CTD |
| G |
Ces3a |
carboxylesterase 3a |
|
decreases expression |
ISO |
19 |
34,929,247 |
34,937,267 |
RGD:6480464 |
CTD |
| G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
increases expression |
ISO |
1 |
12,721,500 |
12,723,943 |
RGD:6480464 |
CTD |
| G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
|
increases expression |
ISO |
4 |
180,650,927 |
180,669,243 |
RGD:6480464 |
CTD |
| G |
Cmpk2 |
cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial |
|
increases expression |
ISO |
6 |
44,128,544 |
44,139,346 |
RGD:6480464 |
CTD |
| G |
Crisp1 |
cysteine-rich secretory protein 1 |
|
decreases expression |
ISO |
9 |
16,975,151 |
17,002,149 |
RGD:6480464 |
CTD |
| G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
3 |
161,542,131 |
161,553,801 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases hydroxylation |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects hydroxylation |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases hydroxylation |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects binding |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases hydroxylation |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
multiple interactions |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases hydrolysis |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects hydrolysis |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
|
increases expression |
ISO |
1 |
82,191,741 |
82,204,629 |
RGD:6480464 |
CTD |
| G |
Defb1 |
defensin beta 1 |
|
decreases expression |
ISO |
16 |
74,980,054 |
74,995,445 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
increases expression |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
increases phosphorylation |
ISO |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
multiple interactions |
ISO |
2 |
236,072,748 |
236,104,714 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
multiple interactions |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
increases expression |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Eln |
elastin |
|
decreases expression |
ISO |
12 |
23,033,657 |
23,077,043 |
RGD:6480464 |
CTD |
| G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
decreases expression |
ISO |
7 |
91,295,824 |
91,377,850 |
RGD:6480464 |
CTD |
| G |
Faah |
fatty acid amide hydrolase |
|
decreases activity |
EXP |
5 |
136,310,965 |
136,329,817 |
RGD:6480464 |
CTD |
| G |
Folr1 |
folate receptor 1 (adult) |
|
decreases expression |
ISO |
1 |
159,315,191 |
159,324,141 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
increases expression |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gdf15 |
growth differentiation factor 15 |
|
multiple interactions |
ISO |
16 |
19,310,882 |
19,313,465 |
RGD:6480464 |
CTD |
| G |
Gpx3 |
glutathione peroxidase 3 |
|
decreases expression |
ISO |
10 |
40,311,094 |
40,319,382 |
RGD:6480464 |
CTD |
| G |
Gsto1 |
glutathione S-transferase omega 1 |
|
increases expression |
ISO |
1 |
253,228,547 |
253,238,531 |
RGD:6480464 |
CTD |
| G |
Gusb |
glucuronidase, beta |
|
multiple interactions |
ISO |
12 |
27,744,409 |
27,757,755 |
RGD:6480464 |
CTD |
| G |
Hells |
helicase, lymphoid specific |
|
increases expression |
ISO |
1 |
243,246,843 |
243,262,459 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
increases activity |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
multiple interactions |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
increases expression |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
|
decreases degradation |
ISO |
16 |
37,419,901 |
37,457,896 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
|
increases expression |
ISO |
19 |
35,336,342 |
35,341,585 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
|
increases expression |
ISO |
1 |
238,559,729 |
238,565,793 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il11 |
interleukin 11 |
|
multiple interactions |
ISO |
1 |
67,784,584 |
67,795,141 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Kcnn4 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
|
decreases expression |
ISO |
1 |
79,613,736 |
79,628,887 |
RGD:6480464 |
CTD |
| G |
Kng1 |
kininogen 1 |
|
multiple interactions |
EXP |
11 |
80,109,499 |
80,131,887 |
RGD:6480464 |
CTD |
| G |
Kng1 |
kininogen 1 |
|
multiple interactions |
EXP |
11 |
80,109,499 |
80,131,887 |
RGD:6480464 |
CTD |
| G |
Lgals3 |
lectin, galactoside-binding, soluble, 3 |
|
increases expression |
ISO |
15 |
23,327,071 |
23,339,006 |
RGD:6480464 |
CTD |
| G |
Lgals9 |
lectin, galactoside-binding, soluble, 9 |
|
decreases expression |
ISO |
10 |
65,129,006 |
65,152,052 |
RGD:6480464 |
CTD |
| G |
Lmo7 |
LIM domain 7 |
|
increases expression |
ISO |
15 |
85,710,975 |
85,928,469 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk11 |
mitogen-activated protein kinase 11 |
|
multiple interactions |
ISO |
7 |
127,444,055 |
127,449,990 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
multiple interactions |
ISO |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mapkapk3 |
mitogen-activated protein kinase-activated protein kinase 3 |
|
multiple interactions |
ISO |
8 |
112,497,626 |
112,531,778 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Msmb |
microseminoprotein, beta |
|
increases expression |
ISO |
16 |
7,619,432 |
7,640,019 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbiz |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta |
|
increases expression |
ISO |
11 |
45,776,027 |
45,811,515 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
multiple interactions |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
increases expression |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Ngfr |
nerve growth factor receptor |
|
multiple interactions |
ISO |
10 |
84,262,804 |
84,281,006 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
ISO |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Oraov1 |
oral cancer overexpressed 1 |
|
decreases expression |
ISO |
1 |
205,342,480 |
205,349,183 |
RGD:6480464 |
CTD |
| G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
|
increases expression |
ISO |
1 |
236,592,414 |
236,677,379 |
RGD:6480464 |
CTD |
| G |
Pcp4 |
Purkinje cell protein 4 |
|
decreases expression |
ISO |
11 |
36,828,273 |
36,889,381 |
RGD:6480464 |
CTD |
| G |
Pdzk1 |
PDZ domain containing 1 |
|
increases expression |
ISO |
2 |
191,643,593 |
191,675,995 |
RGD:6480464 |
CTD |
| G |
Penk |
proenkephalin |
|
decreases expression |
ISO |
5 |
17,509,323 |
17,514,265 |
RGD:6480464 |
CTD |
| G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
|
increases expression |
ISO |
18 |
22,495,197 |
22,579,656 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
multiple interactions |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
multiple interactions |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Psca |
prostate stem cell antigen |
|
increases expression |
ISO |
7 |
112,823,862 |
112,835,190 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases degradation |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rhog |
ras homolog family member G |
|
increases expression |
ISO |
1 |
159,724,016 |
159,735,532 |
RGD:6480464 |
CTD |
| G |
Rxra |
retinoid X receptor alpha |
|
multiple interactions |
ISO |
3 |
6,605,782 |
6,689,224 |
RGD:6480464 |
CTD |
| G |
Sell |
selectin L |
|
decreases expression |
ISO |
13 |
79,827,342 |
79,845,296 |
RGD:6480464 |
CTD |
| G |
Smoc2 |
SPARC related modular calcium binding 2 |
|
decreases expression |
ISO |
1 |
53,165,792 |
53,295,145 |
RGD:6480464 |
CTD |
| G |
Sox2 |
SRY (sex determining region Y)-box 2 |
|
increases expression |
ISO |
2 |
120,969,021 |
120,971,430 |
RGD:6480464 |
CTD |
| G |
Tgoln2 |
trans-golgi network protein 2 |
|
increases expression |
ISO |
4 |
106,110,153 |
106,117,906 |
RGD:6480464 |
CTD |
| G |
Thrsp |
thyroid hormone responsive |
|
multiple interactions |
ISO |
1 |
154,647,339 |
154,651,663 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
multiple interactions |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
decreases response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Twist1 |
twist basic helix-loop-helix transcription factor 1 |
|
decreases expression |
ISO |
6 |
52,605,869 |
52,607,863 |
RGD:6480464 |
CTD |
| G |
Tyms |
thymidylate synthetase |
|
increases expression |
ISO |
9 |
112,604,912 |
112,617,706 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases glucuronidation |
ISO |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
|
increases glucuronidation |
ISO |
9 |
87,081,132 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a6 |
UDP glucuronosyltransferase 1 family, polypeptide A6 |
|
increases glucuronidation |
ISO |
9 |
87,037,154 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a8 |
UDP glycosyltransferase 1 family, polypeptide A8 |
|
increases glucuronidation |
ISO |
9 |
87,017,029 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a9 |
UDP glucuronosyltransferase 1 family, polypeptide A9 |
|
increases glucuronidation |
ISO |
9 |
86,986,915 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases glucuronidation |
ISO |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b7 |
UDP glucuronosyltransferase 2 family, polypeptide B7 |
|
increases glucuronidation |
ISO |
14 |
22,499,152 |
22,522,842 |
RGD:6480464 |
CTD |
Term paths to the root
|